Visx' excimer laser gets approvable recommendation
This article was originally published in Clinica
Executive Summary
Visx' (US) excimer laser system for photorefractive keratectomy received a conditional approval recommendation from the US FDA's ophthalmic devices advisory panel on October 20th. Panel members criticised the company for having incomplete patient follow-up and said they would not recommend approval until two-year follow-up included 90-95% of patients. Visx is seeking marketing approval for use of the laser in patients 18 years and older with -1.0 to -6.0 dioptre myopia with a best corrected vision of at least 20/40.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.